Search Results - therapeutics

HOME SEARCH RSS
4 Results Sort By:
Gene for Successful Aging Without Cognitive Decline
Title: Biomarker for Successful Aging without Cognitive DeclineCurrent State of the Art: It is estimated that up to one third of adults will experience a gradual decline in cognitive function known as mild cognitive impairment as they age. Individuals with cognitive decline are able to function reasonably well in everyday activities, such as managi...
Published: 8/13/2019   |   Inventor(s): Shirley Poduslo
Keywords(s): Aging, Alzheimer's Disease, Therapeutics
Category(s): Diagnostics
Development of Novel Therapies for Experimental Guillain-Barre Syndrome Using Ganglioside-Like Phage-Peptide
Current State of the Art: Guillain Barre syndrome is currently treated by administering pain relievers and other palliative forms of care to reduce the symptoms associated with the disease. Guillain Barre currently affects about 1 out of 50,000 people world-wide and in some instances has proven to be fatal due to limited treatments readily avai...
Published: 8/13/2019   |   Inventor(s): Robert Yu, Seigo Usuki
Keywords(s): Guillain-Barre, Phage-Peptide, Therapeutics
Category(s): Therapeutics
Mitochondrial-Targeted Peptide Modulators of Delta Protein Kinase C Interaction with the d-subunit of F1Fo ATP Synthase/ATPase as Therapeutics Against Cardiac Injury
Current State of the Art: Current clinical therapy for heart attack victims focuses on the rapid restoration of blood flow by thrombolysis, angioplasty, stenting and when appropriate surgical coronary artery bypass grafts. Problems with the Current Art: The majority of cardiac cell death associated with a heart attack actually occurs during ...
Published: 7/26/2019   |   Inventor(s): John Johnson, Tiffany Tuyen Nguyen, Mourad Ogbi
Keywords(s): Cardiovascular, Heart Attack, Therapeutics
Category(s): Therapeutics
Use of JNK Signaling and JNK Inhibitors for the Treatment of Spinal Muscular Atrophy
Current State of the Art: SMA is a devastating neurodegenerative disorder with progressive muscle weakness and loss of motor control due to the loss of neurons in the spinal cord. SMA affects approximately 4 out of every 100,000 people. Children born with SMA Type I, die within 2 years of birth. Those diagnosed with Type II and III can live ...
Published: 7/26/2011   |   Inventor(s): Laxman Gangwani
Keywords(s): Muscular Atrophy, Spinal, Therapeutics
Category(s): Therapeutics
© 2019. All Rights Reserved. Powered by Inteum